Reardon Andrew bought LGND
May 9, 2024 · Form 4 insider transaction
Reardon Andrew bought 10,000 shares of Ligand Pharmaceuticals Incorporated at $52.27 per share, a transaction worth $522.7K. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
10,000
Price
$52.27
Total value
$522.7K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMay 9, 2024
Filing dateMay 13, 2024
Shares owned after32,205
OwnershipDirect
10b5-1 planNo
AmendedNo